A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

Apraglutide

Single dose of apraglutide

Trial Locations (2)

APEX, Münich

Summit Clinical Research, Bratislava

All Listed Sponsors

lead

VectivBio AG

INDUSTRY